Bristol Myers Setback....
Zeposia, an oral S1P modulator, is already approved to treat multiple sclerosis and ulcerative colitis. But when given to adults with moderate to severe active Crohn’s disease, it failed to meet the primary endpoint of clinical remission at week 12 versus placebo, Bristol Myers revealed Thursday.
https://endpts.com/bristol-myers-zeposia-fails-phase-3-crohns-disease-study/
banter and General Discussion, page-9323
-
- There are more pages in this discussion • 2,003 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.51 |
Change
0.020(1.34%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.58 | $1.41 | $13.97M | 9.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 72002 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.51 | 1566 | 4 |
View Market Depth
| Last trade - 14.11pm 07/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |